tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

EyePoint Pharmaceuticals Raises $141M in Public Offering

Story Highlights
  • EyePoint Pharmaceuticals announced a public offering of shares and pre-funded warrants on October 14, 2025.
  • The offering raised $141 million to support DURAVYU™ development and pipeline initiatives.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
EyePoint Pharmaceuticals Raises $141M in Public Offering

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

EyePoint Pharmaceuticals ( (EYPT) ) has shared an announcement.

On October 14, 2025, EyePoint Pharmaceuticals announced an underwritten public offering of 11,000,000 shares of its common stock and pre-funded warrants for 1,500,000 shares, raising approximately $141 million. The offering, which closed on October 16, 2025, aims to fund the clinical development of DURAVYU™ and support pipeline initiatives. This move is expected to bolster EyePoint’s financial position and advance its strategic objectives in the biopharmaceutical industry.

The most recent analyst rating on (EYPT) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

Spark’s Take on EYPT Stock

According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.

EyePoint Pharmaceuticals’ overall stock score reflects a mix of strong clinical progress and financial challenges. The most significant factor is the company’s robust cash position and clinical trial advancements, which are offset by current profitability issues and negative cash flows. Technical indicators suggest potential for a rebound, while valuation remains challenging due to ongoing losses.

To see Spark’s full report on EYPT stock, click here.

More about EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases. The company’s lead product candidate, DURAVYU™, is an investigational treatment for VEGF-mediated retinal diseases, currently in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. EyePoint is headquartered in Watertown, Massachusetts, and has a commercial manufacturing facility in Northbridge, Massachusetts.

Average Trading Volume: 943,015

Technical Sentiment Signal: Hold

Current Market Cap: $796.1M

See more data about EYPT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1